1. Introduction {#sec1}
===============

Neuropathic pain (NP) is a common condition globally \[[@B1]\]. With a complex pathogenesis, reliable treatments are currently unavailable; consequently, NP has a substantial negative impact on quality of life, and it causes a heavy social burden. NP was defined by the International Pain Society in 2011 as "damaged by the somatosensory nervous system or pain caused by disease" \[[@B2]\]. The clinical symptoms of NP mainly include hyperalgesia, allodynia, and spontaneous pain \[[@B3]\]. NP has a high incidence, accounting for approximately one-fifth of all cases of chronic pain, thereby causing significant damage to patients\' physical and mental health \[[@B4]\]. In addition, NP remains a major focus of both clinical medicine and basic research.

Qi She Pill (QSP) has been approved by the China Food and Drug Administration (approval number: Z20090978), and it is widely available in China \[[@B5]\]. QSP is composed of six Chinese herbs, namely Caulis Sinomenii (CS, Qing Feng Teng), Calculus Bovis (BC, Niu Huang), Chuanxiong Rhizoma (CR, Chuan Xiong), Stephaniae Tetrandrae Radix (STR, Fang Ji), Hedysarum Multijugum Maxim (HMM, Huang Qi), and Moschus (MO, She Xiang). QSP has several effects, such as improving Qi, dissipating phlegm, eliminating stagnation, and relieving pain \[[@B6]\].

Preclinical pharmacological studies reported that QSP has analgesic effects and obvious anti-inflammatory effects against acute and chronic inflammation \[[@B7]\]. Pathology studies found that QSP can suppress NP. Furthermore, clinical trials proved that QSP effectively relieves pain and improves clinical symptoms and that the therapy is safe for treating NP. Phase II and III clinical trials of QSP also verified its clinical effect in patients with NP, and no obvious adverse effects were identified. QSP is widely used to treat NP in China.

The development of network pharmacology \[[@B8]\] has been bolstered by the rapid development of multidisciplinary fields such as pharmacy, computer science, biology, and systems biology \[[@B9]\]. The comprehensive observation of drugs using network pharmacology systems is achieved through network analysis covering a wide range of diseases, genes, targets, and drug networks. The results of this analysis illustrate that a disease can be regulated by a variety of different proteins/genes, and some proteins can also be regulated by a variety of diseases. Such results fully reflect the theory of traditional Chinese medicine (TCM) that the same disease can be treated with different methods and that different diseases can be treated with the same methods. In-depth studies of TCM compounds revealed the material basis and molecular mechanism of Chinese medicine pharmacodynamics \[[@B10]\].

Although the analgesic effects and chemical profiling of QSP have been reported, the active compounds in QSP and the specific molecular mechanisms of QSP in treating NP are unclear, and network pharmacology-based prediction of the bioactive components and their target pathways has not been performed. Therefore, the present study explored the pharmacological mechanisms by which QSP alleviates NP and investigated the relationships among herbs, compounds, and target genes by employing QSP-based network pharmacology. First, we collected information on the bioactive compounds in QSP and retrieved candidate target genes from public databases. Network analysis was then performed to connect compounds in QSP with their target genes and related signaling pathways. Finally, based on the results of network analysis, multicompound, multitarget, and multipathway mechanisms related to QSP were predicted. The workflow is shown in [Figure 1](#fig1){ref-type="fig"}.

2. Methods {#sec2}
==========

2.1. Collection and Treatment of Active Compounds and Targets in QSP {#sec2.1}
--------------------------------------------------------------------

The chemical components of CS, BC, CR, STR, and HMM meeting the criteria of oral bioavailability (OB) \>30% and drug likeness (DL) \>0.18 were selected as candidate active components using the Traditional Chinese Medicine Systems Pharmacology (TCMSP) database \[[@B11]\], and their potential targets were retrieved \[[@B12], [@B13]\]. The chemical components of MO were determined using the BATMAN-TCM server \[[@B14]\], and the principle of "drug-target similarity" was used to set the threshold "score cutoff = 30" to calculate the potential targets corresponding to chemical components.

2.2. Prediction of the Targets of Active Ingredients and Construction of the Active Ingredient-Target Network Map of QSP {#sec2.2}
------------------------------------------------------------------------------------------------------------------------

Potential protein targets of QSP were screened using the TCMSP database, and all retrieved target proteins were corrected to the official symbols using the UniProt database. The network diagram of "active component-biological target" was constructed using Cytoscape 3.2.1 software \[[@B15]\]. Nodes in the network represent active components and biological targets. Active components and biological targets were connected by edges.

2.3. Retrieval of Relevant Biological Targets for NP {#sec2.3}
----------------------------------------------------

In this study, "neuropathic pain" was used as the search term to retrieve recognized biological targets using various databases (TTD \[[@B16]\], DrugBank \[[@B17]\], DisGeNET \[[@B18]\], GAD \[[@B19]\], and PharmGKB \[[@B20]\]), and the search results were used to identify currently known biological targets related to NP. Because of the poor uniformity of biological target information sources, the UniProt ID of each target was obtained by correcting the target protein and gene information screened via protein database retrieval \[[@B21]\].

2.4. Construction of the Protein-Protein Interaction (PPI) Network Diagram and Screening of Key Biological Targets {#sec2.4}
------------------------------------------------------------------------------------------------------------------

The network diagram of PPIs is an important method for identifying direct and indirect interactions between targets \[[@B22]\]. The PPI network was constructed using the STRING platform, and the species was set as "*Homo sapiens* \[[@B23]\]." The minimum threshold of interaction was set as "medium confidence = 0.4," which was used to draw the PPI maps of the active components of QSP and PPI maps of NP-related targets. The "Network Analyzer" function of Cytoscape 3.2.1 \[[@B24]\] was utilized to analyze the topological properties of PPI network and calculate two important topological parameters: "node degree distribution" and "betweenness centrality" of the overall network. The node degree reflects the number of connections with other nodes, whereas betweenness reflects a network of all of the shortest paths through a node in the path. These measures indicate the importance of a node in the network and determine whether a target protein is a "core target." To study the possible pharmacological effects of a core target, the mean degree and betweenness are taken as the "card value," and the target between degree and betweenness on the card value is selected as the "core target \[[@B25]\]."

2.5. Gene Ontology (GO) Enrichment Analysis of NP-Related Targets following QSP Treatment {#sec2.5}
-----------------------------------------------------------------------------------------

To illustrate the QSP treatment target NP protein in the role of gene function, this study uses David \[[@B26]\] analysis QSP PPI for the treatment of NP protein involved in the network GO function analysis of enrichment. According to the number of targets involves sorting, the first few biological processes establish GO bioprocess enrichment and analyze the possible bioprocesses of core targets in the body.

2.6. Kyoto Gene and Genomics Encyclopedia (KEGG) Pathway Enrichment Analysis of the Targets of QSP in the Treatment of NP {#sec2.6}
-------------------------------------------------------------------------------------------------------------------------

Using DAVID, the protein targets of QSP in the treatment of NP were examined using KEGG signaling pathway enrichment \[[@B27]\]. The correlation between core targets and NP in the KEGG signal pathway and clear QSP possible pharmacological mechanism is researched. By using Cytoscape 3.2.1 software, the KEGG pathway of "drug---active ingredient---target---pathway" network is constructed. The results of the enrichment analysis of visualization were processed by ImageGP software.

3. Results {#sec3}
==========

3.1. Screening of the Active Ingredients in QSP {#sec3.1}
-----------------------------------------------

QSP consists of CS, BC, CR, STR, HMM, and MO. Using the TCMSP database, a total of 361 compounds were retrieved, including 16 in CS, 19 in BC, 189 in CR, 50 in STR, and 87 in HMM. Of the 16 compounds in CS, six satisfied the criteria of OB ≥ 30% and DL ≥ 0.18. Of the 19 compounds in BC, five satisfied the criteria of OB ≥ 30% and DL ≥ 0.18. Of the 189 compounds in CR, 115 satisfied the criteria of OB ≥ 30%, whereas seven satisfied the criteria of OB ≥ 30% and DL ≥ 0.18. Of the 50 compounds in STR, all satisfied the criteria of OB ≥ 30% and four satisfied the criteria of OB ≥ 30% and DL ≥ 0.18. Of the 87 compounds in HMM, 44 satisfied the criteria of OB ≥ 30% and 20 satisfied the criteria of OB ≥ 30% and DL ≥ 0.15. Thus, 42 of the total 361 compounds satisfied the criteria, and 37 compounds were finally obtained after excluding duplicates. BATMAN-TCM was used to excavate 30 active components of MO, and 25 active components were obtained after excluding five components not meeting the score cutoff of 30. The remaining 60 active ingredients were removed after deleting duplicates. The resulting network of the final selected compounds from the six herbal medicines is shown in [Table 1](#tab1){ref-type="table"}.

3.2. Prediction of the Targets of QSP and Construction of an Active Component-Target Network Diagram {#sec3.2}
----------------------------------------------------------------------------------------------------

Using the TCMSP database, 706 potential targets of CS, BC, CR, STR, and HMM were screened, and 734 potential targets of MO in astragalus musk deer pills were screened using the BATMAN-TCM database. The remaining 444 targets were eliminated after deleting duplicates. Compounds were linked to biological targets, and networks of active-component-target interactions were plotted using Cytoscape 3.2.1 software. Network diagrams more intuitively reflect the interactions of these compounds with targets. It was found that the network diagram contained 504 nodes, and the interaction network between drugs and targets contained 1425 edges. The 504 nodes included 60 active components of QSP. Quercetin acted on 151 targets, and beta-sitosterol acted on 74 targets. PTGS2 had a total of 28 potential targets, followed by 24 targets for PTGS1. This fully reflects the complex network relationship between multiple targets, verifying that QSP functions in a multichannel, multilink, multitarget, and integrated synergistic manner. These genes, proteins, compounds, and herbs are listed in Supplementary [Table 1](#tab1){ref-type="table"}, and the resulting herb-compound-target gene network is shown in [Figure 2](#fig2){ref-type="fig"}. The key nodes and topological properties of the active component-target network are shown in [Table 2](#tab2){ref-type="table"}.

3.3. Retrieval of NP-Related Targets {#sec3.3}
------------------------------------

By searching databases such as TTD, DrugBank, DisGeNET, GAD, and PharmGKB, a total of 70 QSP targets related to the occurrence and development of NP were identified after deleting repeated targets, as shown in Supplementary [Table 2](#tab2){ref-type="table"}.

3.4. Construction of the PPI Network for the Treatment of NP by the Active Ingredients of QSP and the Screening and Analysis of Key Targets {#sec3.4}
-------------------------------------------------------------------------------------------------------------------------------------------

The PPI network of the active components of QSP was constructed using STRING ([Figure 3](#fig3){ref-type="fig"}), and the results revealed 434 direct or indirect targets and 7070 interactions between the targets. At the same time, the PPI network graph of NP-related targets identified 66 targets directly or indirectly related to the selected targets ([Figure 4](#fig4){ref-type="fig"}). In total, 324 interactions were identified between the targets. Cytoscape was used to extract the intersection network in the PPI network graph and delete targets without intersections. The screening principle was that when the active components in the vine acted on an NP target, the active components were associated with NP. In total, 48 potential targets were analyzed. There were 191 interactions between targets. [Figure 5](#fig5){ref-type="fig"} presents the PPI network of the NP-related targets of the active ingredients of QSP. [Table 3](#tab3){ref-type="table"} presents information about the targets in the PPI network in the treatment of NP by QSP. Cytoscape 3.2.1 software was used to create an active component-target interaction network. The network map more intuitively reflects the interactions of the active components of QSP with NP-related targets.

Analysis of the network of active ingredient-target interactions revealed that the network map contained 90 nodes and 296 edges. The 90 nodes included 42 active components of QSP in blood and 48 targets of QSP. The active ingredients of QSP and NP target network are shown in [Figure 6](#fig6){ref-type="fig"}. In the subsequent experiment, Network Analyzer topology properties were used to filter key targets. After a target is screened according to the network topology theory, it can affect more nodes, increasing the efficiency of network information transmission. This study screened 10 key targets: DRD2, CHRM2, *β*2-adrenergic receptor (ADRB2), HTR7, OPRM1, HTR2A, SLC6A4, HTR2C, CHRM1, and calcitonin gene-related peptide (CALCA). The interaction between the target and the target is 18 sides. [Table 4](#tab4){ref-type="table"} shows the 10 key nodes and the topological properties of QSP in the NP-related target PPI network.

3.5. GO Biological Process Annotation for NP-Related Targets of QSP {#sec3.5}
-------------------------------------------------------------------

Using the GO bioprocess enrichment analysis function of the DAVID platform, the functions of the 48 proteins in the PPI network of QSP in the treatment of NP were studied, and 53 GO entries were determined using a false discovery rate (FDR) of \<0.05. The 53 GO entries are listed in Supplementary [Table 3](#tab3){ref-type="table"}. GO is an analytical method for classifying genes according to their function, which can be divided into three parts: biological process, molecular function, and cell composition. GO analysis identifies important functions that cause a trait to change, and the gene corresponding to the function is revealed. Among them, 35 items were related to biological processes, including the regulation of systemic processes, multicellular biological processes, signal transduction, cell proliferation, and response to stimuli. Meanwhile, seven items related to molecular function were found, including items linked to receptor activity, neurotransmitter binding, drug binding, and adrenaline binding, and 11 related items were related to cell composition, including items related to the plasma membrane, synapses, and dendrites.

3.6. KEGG Pathway Enrichment Analysis of QSP in the Treatment of NP {#sec3.6}
-------------------------------------------------------------------

KEGG pathway enrichment analysis was performed using DAVID. The pathways of 48 proteins involved in PPI network of NP-related targets of QSP were analyzed via pathway enrichment, and 24 signaling pathways were obtained. According to the principle of FDR \<0.05, eight signaling pathways, including calcium signaling and neural active ligand-receptor interaction signaling pathways, were identified, indicating that the active components of QSP can act on these signaling pathways in the treatment of NP. [Table 5](#tab5){ref-type="table"} shows the pathways for QSP in the treatment of NP target. The enrichment analysis results were visualized using Image GP software. The bubble size in the figure represents the number of genes enriched in the pathway. The difference in bubble color represents the degree of enrichment of the target gene in the pathway. The bubble diagram is shown in [Figure 7](#fig7){ref-type="fig"}. In this study, 32 genes were enriched in the neuroactive ligand-receptor interaction signaling pathway, 19 genes were enriched in the calcium signaling pathway, and 11 genes were enriched in the cAMP signaling pathway.

3.7. Construction of the Drug-Active Ingredient-Target-Pathway Network Diagram of QSP in the Treatment of NP {#sec3.7}
------------------------------------------------------------------------------------------------------------

The drug-active ingredient-target-pathway network model map of QSP was constructed using Cytoscape 3.2.1 software. The map included 103 nodes, including 5 drugs, 42 active components, and 48 target proteins. The metabolic pathways were connected by 444 edges to form a complete network. [Figure 8](#fig8){ref-type="fig"} presents the drug-active ingredient-target-pathway network diagram.

4. Discussion {#sec4}
=============

TCMSP is a system-level pharmacological database of TCM that provides systematic TCM information, and it is a platform for the development of new drugs for the treatment of human diseases. After a critical review of pharmacological and clinical knowledge, the TCMSP collected all 499 herbs registered in the 2010 edition of the Chinese Pharmacopoeia, totaling 12,144 compounds \[[@B11]\]. BATMAN-TCM is the first online bioinformatics analysis tool of TCM molecular mechanisms, and it is used to clarify the "multicomponent, multitarget, and multipathway" combinatorial therapeutic mechanism of TCM and provide valuable clues for subsequent experimental validation, thus accelerating the elucidation of the molecular mechanisms of TCMs \[[@B14]\]. It is the first step of network pharmacology analysis for identifying chemical components and their target information as completely as possible. The collection of the chemical constituents of QSP is accurate and complete using the two databases currently recognized for network pharmacology research.

QSP can relieve pain and promote blood circulation. The drug has been widely used in China. Clinical studies revealed that QSP can significantly improve mild-to-moderate NP and improve the quality of life of patients with mild-to-moderate NP, especially concerning physiological function, social function, emotional function, vitality, and other aspects. In a number of randomized, double-blind, placebo-controlled studies, improvements in dysfunction associated with mild-to-moderate NP were observed in both the QSP and placebo group, although the improvement was significantly better in the QSP group \[[@B5]\]. To study the mechanism of action of QSP, this study relied on the TCMSP and BATMAN-TCM platforms to study the active constituents of six Chinese herbs (CS, BC, CR, STR, HMM, and MO) and constructed a compound-target network to analyze the direct interactions between compounds and targets. These findings provided a reference for the multicomponent, multitarget, and multipath treatment mechanism of QSP. The results of this study suggest that QSP most likely exerts its therapeutic effects on NP through interactions among MOL021, MOL001, PTGS2, and PTGS1, thereby laying a foundation for subsequent confirmatory studies. The key compounds of QSP in the target network included quercetin and beta-sitosterol, which had much higher degrees than other compounds, and beta-sitosterol was detected in both CS and STR. It can thus be speculated that CS and STR play key roles in the effects of QSP \[[@B28]\]. Prior research indicated that beta-sitosterol has a wide range of pharmacological effects including anti-inflammatory, immunomodulatory, antioxidant, and analgesic effects \[[@B29]\]. Quercetin can lower blood pressure, enhance capillary resistance, and reduce capillary fragility \[[@B30]\]. The key targets of QSP in the key target network included PTGS1 and PTGS2. PTGS is a key rate-limiting enzyme for the synthesis of prostaglandins from arachidonic acid \[[@B31]\], and two isomerases, namely, PTGS1 and PTGS2, have been identified. PTGS and its products are involved in various physiological and pathological processes such as inflammatory responses and blood coagulation balance \[[@B32]\]. Ten key target proteins were screened using the Network Analyzer topology properties in the PPI network for the treatment of NP by the active ingredients of QSP. It was previously found that DRD2 is the major receptor for NP \[[@B33]\], and KLF15 is induced in NP in a TNF-α-dependent manner. KLF15 induces NP by promoting the expression of the DRD2 receptor. NP is associated with persistent changes in gene expression in primary sensory neurons, but the underlying epigenetic mechanisms leading to these changes are unclear. In addition, CHRM plays a key role in the regulation of spinal cord nociceptive transmission \[[@B34]\]. Norepinephrine and the adrenergic system control the transmission of damage at the level of the spinal cord and play a key role in this process. Stimulation of ADRB2 downregulates the phosphorylation of p38 MAPK in microglia and JNK in astrocytes. The aforementioned studies indicated that spinal ADRB2 regulates MAPK phosphorylation and downregulates glial activity, thereby inhibiting neuropathic damage conduction at the spinal cord level \[[@B35]\]. The HTR family is involved in the central nociceptive mechanism, which plays a key role in suppressing analgesic pathways, and its stimulation can regulate neuronal signaling induced by neuropathy \[[@B36]\]. Animal studies revealed that CALCA expressed in dorsal root ganglia is involved in the generation and maintenance of NP \[[@B37]\]. Based on the aforementioned information, it is speculated that the testes directly or indirectly act on these key targets to play a pharmacological role in the treatment of NP.

PPI networks are composed of individual proteins interacting with each other to participate in biological signal transmission, gene expression regulation, energy and substance metabolism, cell cycle regulation, and other aspects of life processes. It is of great significance to understand the functional connection between proteins \[[@B22]\]. Enrichment analysis is helpful for studying gene and expression information as a whole network. In organisms, different gene products coordinate with each other to perform biological functions, and pathway annotation analysis of differentially expressed genes is helpful for further interpreting gene functions \[[@B26], [@B27]\]. In this study, we preliminarily explored the primary pathway of QSP in treating NP using PPI network and enrichment analyses. In the present study, the analysis yielded the following results. Of the 5 herbs and 42 compounds examined, a total of 48 target genes were associated with NP. To illustrate the role of the active targets of QSP in gene function and signaling pathways, GO functional enrichment and KEGG pathway enrichment analyses of the 48 genes in the PPI network were performed. GO function enrichment analysis found that the effects of QSP in the treatment of NP are mainly reflected in the regulation of receptor activity, plasma membrane, and systemic processes. The main KEGG pathways involved in the treatment of NP by QSP included calcium signaling and neuroactive ligand-receptor interaction signaling pathways. From the aforementioned studies, it is concluded that the active components of QSP alleviate NP by acting on these signaling pathways. A neuroactive ligand-receptor interaction signaling pathway is a collection of receptor ligands on the plasma membrane that are associated with intracellular and extracellular signaling pathways and are closely related physiologically to neurological function \[[@B38]\]. Key molecules in the calcium signaling pathway have a variety of biological functions, among which calcium ions play an important role in maintaining biopotential \[[@B39]\], maintaining normal nerve conduction function \[[@B40]\], and regulating physiological actions including intracellular enzyme activity, muscle contraction and relaxation \[[@B41]\], nervous system function \[[@B42]\], stimulation and secretion-coupled participation \[[@B43]\], glucose metabolism \[[@B44]\], and prostaglandin \[[@B45]\] and insulin synthesis \[[@B46]\].

Network pharmacology combines the concepts of systems biology and multidirectional pharmacology \[[@B47]\]. It explores the relationship between drugs and diseases from a holistic perspective, emphasizing the holistic and systematic interactions among drugs, targets, and diseases \[[@B48]\]. The Chinese herb system is a multicomponent complex system. Bioinformatic and network pharmacology research helps to both clarify the mechanism of action of QSP in the treatment of NP and provide an important theoretical basis for further discussion of subsequent molecular mechanisms and optimization of experimental design. This research also provides new ideas and methods for the research and development of new Chinese herbs and elucidation of the related mechanisms of drugs and diseases \[[@B49]\]. Meanwhile, some limitations of this study must be addressed. First, because of limitations regarding screening conditions, only the main compounds in QSP could be analyzed, and thus the research results are limited to some extent. Second, although a large number of targets and pathways can be screened using network pharmacology, these results need to be verified via pharmacological experiments. Third, further validation experiments are needed to increase the drug concentration to accurately reveal the effective ingredients and mechanism of QSP in the treatment of NP.

5. Conclusion {#sec5}
=============

The network pharmacology analysis of QSP identified 444 compounds in six herbs, and 48 of the compounds in the six herbs were screened to identify NP-related target genes. This study demonstrated that network pharmacology studies can reveal close interactions between multiple components and multiple targets. The network pharmacology approach of this study provides another research strategy for a comprehensive understanding of the mechanism by which QSP treats NP.
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![The workflow of network pharmacology analysis.](ECAM2020-7193832.001){#fig1}

![The herb-compound-target gene network consisting of six herbal medicines (green hexagons), 60 compounds (pink rectangles), and 444 target genes (sky-blue ovals).](ECAM2020-7193832.002){#fig2}

![The PPI network of the active components of QSP.](ECAM2020-7193832.003){#fig3}

![The PPI network graph of NP-related targets.](ECAM2020-7193832.004){#fig4}

![The PPI network of the NP-related targets of the active ingredients of QSP.](ECAM2020-7193832.005){#fig5}

![The active ingredients of QSP and NP target network through a network of 42 compounds (pink rectangles) and 48 target genes (sky-blue ovals).](ECAM2020-7193832.006){#fig6}

![The bubble diagram of KEGG mechanism analysis.](ECAM2020-7193832.007){#fig7}

![The drug-active ingredient-target-pathway network diagram of a network of five herbs (green hexagons), 42 compounds (pink rectangles), 48 target genes (sky-blue ovals), and 8 pathways (orange triangles).](ECAM2020-7193832.008){#fig8}

###### 

The resulting network of the final selected compounds from the six herbal medicines.

  Number   Molecule name                                                                                                                                                                            OB      DL     Herb name
  -------- ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- ------- ------ -----------
  MOL001   Beta-sitosterol                                                                                                                                                                          36.91   0.75   CS/STR
  MOL002   16-Epi-isositsirikine                                                                                                                                                                    49.52   0.59   CS
  MOL003   Magnograndiolide                                                                                                                                                                         63.71   0.19   CS
  MOL004   Michelenolide                                                                                                                                                                            47.54   0.25   CS
  MOL005   Sinomenine                                                                                                                                                                               46.09   0.53   CS
  MOL006   Stepholidine                                                                                                                                                                             33.11   0.54   CS
  MOL007   CLR                                                                                                                                                                                      37.87   0.68   BC
  MOL008   Methyl (4R)-4-\[(3R,5S,7S,8R,9S,10S,12S,13R,14S,17R)-3,7,12-trihydroxy-10,13-dimethyl-2,3,4,5,6,7,8,9,11,12,14,15,16,17-tetradecahydro-1H-cyclopenta\[a\]phenanthren-17-yl\]pentanoate   32.32   0.76   BC
  MOL009   Methyl desoxycholate                                                                                                                                                                     34.63   0.73   BC
  MOL010   Deoxycholic acid                                                                                                                                                                         40.72   0.68   BC
  MOL011   ZINC01280365                                                                                                                                                                             46.38   0.49   BC
  MOL012   Sitosterol                                                                                                                                                                               36.91   0.75   CR
  MOL013   FA                                                                                                                                                                                       68.96   0.71   CR/HMM
  MOL014   Mandenol                                                                                                                                                                                 42      0.19   CR
  MOL015   Myricanone                                                                                                                                                                               40.6    0.51   CR
  MOL016   Perlolyrine                                                                                                                                                                              65.95   0.27   CR
  MOL017   Wallichilide                                                                                                                                                                             42.31   0.71   CR
  MOL018   *N*-Methylflindersine                                                                                                                                                                    32.36   0.18   STR
  MOL019   Hesperetin                                                                                                                                                                               70.31   0.27   STR
  MOL020   (3S,8S,9S,10R,13R,14S,17R)-10,13-Dimethyl-17-\[(2R,5S)-5-propan-2-yloctan-2-yl\]-2,3,4,7,8,9,11,12,14,15,16,17-dodecahydro-1H-cyclopenta\[a\]phenanthren-3-ol                            36.23   0.78   HMM
  MOL021   Quercetin                                                                                                                                                                                46.43   0.28   HMM
  MOL022   Mairin                                                                                                                                                                                   55.38   0.78   HMM
  MOL023   Jaranol                                                                                                                                                                                  50.83   0.29   HMM
  MOL024   Hederagenin                                                                                                                                                                              36.91   0.75   HMM
  MOL025   Isorhamnetin                                                                                                                                                                             49.6    0.31   HMM
  MOL026   3,9-Di-O-methylnissolin                                                                                                                                                                  53.74   0.48   HMM
  MOL027   7-O-Methylisomucronulatol                                                                                                                                                                74.69   0.3    HMM
  MOL028   9,10-Dimethoxypterocarpan-3-O-*β*-D-glucoside                                                                                                                                            36.74   0.92   HMM
  MOL029   (6aR,11aR)-9,10-Dimethoxy-6a,11a-dihydro-6H-benzofurano \[3,2-c\]chromen-3-ol                                                                                                            64.26   0.42   HMM
  MOL030   Bifendate                                                                                                                                                                                31.1    0.67   HMM
  MOL031   Formononetin                                                                                                                                                                             69.67   0.21   HMM
  MOL032   Calycosin                                                                                                                                                                                47.75   0.24   HMM
  MOL033   Kaempferol                                                                                                                                                                               41.88   0.24   HMM
  MOL034   Isomucronulatol-7,2′-di-O-glucosiole                                                                                                                                                     49.28   0.62   HMM
  MOL035   1,7-Dihydroxy-3,9-dimethoxy pterocarpene                                                                                                                                                 39.05   0.48   HMM
  MOL036   Androst-4-ene-3,17-dione                                                                                                                                                                 ---     ---    MO
  MOL037   Testosterone                                                                                                                                                                             ---     ---    MO
  MOL038   3,5-Dihydroxybenzoic acid                                                                                                                                                                ---     ---    MO
  MOL039   Musennin                                                                                                                                                                                 ---     ---    MO
  MOL040   17-Beta-estradiol                                                                                                                                                                        ---     ---    MO
  MOL041   Allantoin                                                                                                                                                                                ---     ---    MO
  MOL042   3-Methylcyclotridecan-1-one                                                                                                                                                              ---     ---    MO
  MOL043   Muscopyridine                                                                                                                                                                            ---     ---    MO
  MOL044   5-*cis*-Cyclopentadecen-1-one                                                                                                                                                            ---     ---    MO
  MOL045   Decamine                                                                                                                                                                                 ---     ---    MO
  MOL046   Musclide A1                                                                                                                                                                              ---     ---    MO
  MOL047   Estragole                                                                                                                                                                                ---     ---    MO
  MOL048   Cyclotetradecan-1-one                                                                                                                                                                    ---     ---    MO
  MOL049   3beta-Hydroxy-5alpha-androstan-17-one                                                                                                                                                    ---     ---    MO
  MOL050   Alpha-estradiol                                                                                                                                                                          ---     ---    MO
  MOL051   Androsterone                                                                                                                                                                             ---     ---    MO
  MOL052   Cyclovirobuxine                                                                                                                                                                          ---     ---    MO
  MOL053   Cholesterol                                                                                                                                                                              ---     ---    MO
  MOL054   Muscone                                                                                                                                                                                  ---     ---    MO
  MOL055   2,6-Decamethylene pyridine                                                                                                                                                               ---     ---    MO
  MOL056   3alpha-Hydroxy-5alpha-androstan-17-one                                                                                                                                                   ---     ---    MO
  MOL057   Muscol                                                                                                                                                                                   ---     ---    MO
  MOL058   Normuscone                                                                                                                                                                               ---     ---    MO
  MOL059   2,6-Nonamethylene pyridine                                                                                                                                                               ---     ---    MO
  MOL060   5-*cis*-Cyclotetradecen-1-one                                                                                                                                                            ---     ---    MO

###### 

The key nodes and topological properties of the active component-target network.

  Name     Category   Degree   Betweenness
  -------- ---------- -------- -------------
  MOL021   Compound   152      0.36805645
  MOL001   Compound   76       0.0386247
  PTGS2    Target     28       0.04871355
  PTGS1    Target     24       0.04082273

###### 

The gene, target name, and Uniprot ID in the PPI network in the treatment of NP by QSP.

  Number   Gene      Target name                                                        Uniprot ID
  -------- --------- ------------------------------------------------------------------ ------------
  1        ABCB1     Multidrug resistance protein 1                                     P08183
  2        ADORA1    Adenosine receptor A1                                              P30542
  3        ADORA2A   Adenosine receptor A2a                                             P29274
  4        ADRA1A    Alpha-1A adrenergic receptor                                       P35348
  5        ADRA1B    Alpha-1B adrenergic receptor                                       P35368
  6        ADRA1D    Alpha-1D adrenergic receptor                                       P25100
  7        ADRA2A    Alpha-2A adrenergic receptor                                       P08913
  8        ADRA2B    Alpha-2B adrenergic receptor                                       P18089
  9        ADRA2C    Alpha-2C adrenergic receptor                                       P18825
  10       ADRB1     Beta-1 adrenergic receptor                                         P08588
  11       ADRB2     Beta-2 adrenergic receptor                                         P07550
  12       CACNA1A   Voltage-dependent P/Q-type calcium channel subunit alpha-1A        O00555
  13       CACNA1B   Voltage-dependent *N*-type calcium channel subunit alpha-1B        Q00975
  14       CALCA     Calcitonin gene-related peptide 1                                  P06881
  15       CHRM1     Muscarinic acetylcholine receptor M1                               P11229
  16       CHRM2     Muscarinic acetylcholine receptor M2                               P08172
  17       CHRM3     Muscarinic acetylcholine receptor M3                               P20309
  18       CHRM4     Muscarinic acetylcholine receptor M4                               P08173
  19       CHRM5     Muscarinic acetylcholine receptor M5                               P08912
  20       DRD1      Dopamine D1 receptor                                               P21728
  21       DRD2      D(2) dopamine receptor                                             P14416
  22       DRD5      D(1B) dopamine receptor                                            P21918
  23       ESR1      Estrogen receptor                                                  P03372
  24       GABRA2    Gamma-aminobutyric-acid receptor alpha-2 subunit                   P47869
  25       GABRD     Gamma-aminobutyric acid receptor subunit delta                     O14764
  26       GABRG3    Gamma-aminobutyric acid receptor subunit gamma-3                   Q99928
  27       GRIN2B    Glutamate ionotropic receptor NMDA type subunit 2B                 Q13224
  28       HRH1      Histamine H1 receptor                                              P35367
  29       HRH2      Histamine H2 receptor                                              P25021
  30       HTR1A     5-Hydroxytryptamine receptor 1A                                    P08908
  31       HTR2A     5-Hydroxytryptamine 2A receptor                                    P28223
  32       HTR2C     5-Hydroxytryptamine 2C receptor                                    P28335
  33       HTR7      5-Hydroxytryptamine receptor 7                                     P34969
  34       KCNH2     Potassium voltage-gated channel subfamily D member 2               Q9NZV8
  35       MAOB      Amine oxidase \[flavin-containing\] B                              P27338
  36       OPRD1     Delta-type opioid receptor                                         P41143
  37       OPRK1     Opioid receptor kappa 1                                            P41145
  38       OPRM1     Opioid receptor mu 1                                               P35372
  39       PTGS1     Prostaglandin G/H synthase 1                                       P23219
  40       PTGS2     Prostaglandin G/H synthase 2                                       P35354
  41       SCN10A    Sodium voltage-gated channel alpha subunit 10                      Q9Y5Y9
  42       SCN1A     Sodium voltage-gated channel alpha subunit 1                       P35498
  43       SLC6A2    Sodium-dependent noradrenaline transporter                         P23975
  44       SLC6A3    Sodium-dependent dopamine transporter                              Q01959
  45       SLC6A4    Sodium-dependent serotonin transporter                             P31645
  46       TNF       Tumor necrosis factor                                              P01375
  47       TRPM8     Transient receptor potential cation channel subfamily M member 8   Q7Z2W7
  48       TRPV1     Transient receptor potential cation channel subfamily V member 1   Q8NER1

###### 

Ten key nodes in QSP treatment of NP target PPI networks and their topological properties.

  Name     Degree   Betweenness
  -------- -------- -------------
  DRD2     17       0.0853782
  CHRM2    15       0.2364376
  ADRB2    12       0.10820742
  HTR7     12       0.07132715
  OPRM1    12       0.06858521
  HTR2A    12       0.06496394
  SLC6A4   11       0.12727011
  HTR2C    11       0.04633399
  CHRM1    10       0.08797099
  CALCA    9        0.04503978

###### 

The pathways for QSP in the treatment of NP target (FDR \< 0.05).

  Name       Term                                      Count   Genes                                                                                                                                                                                                                                  *P* value      FDR
  ---------- ----------------------------------------- ------- -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- -------------- --------------
  hsa04080   Neuroactive ligand-receptor interaction   32      OPRM1, DRD1, TRPV1, ADORA2A, DRD2, DRD5, OPRK1, ADORA1, HRH1, HTR1A, GRIN2B, HRH2, ADRA2A, ADRA2C, ADRA2B, GABRD, GABRA2, GABRG3, ADRB2, CHRM5, ADRB1, CHRM4, CHRM3, CHRM2, HTR7, CHRM1, ADRA1B, ADRA1A, HTR2C, ADRA1D, HTR2A, OPRD1   1.05*E* − 34   1.18*E* − 31
                                                                                                                                                                                                                                                                                                                     
  hsa04020   Calcium signaling pathway                 19      DRD1, ADORA2A, DRD5, CHRM5, HRH1, ADRB2, ADRB1, CHRM3, HRH2, CHRM2, CHRM1, HTR7, ADRA1B, ADRA1A, HTR2C, ADRA1D, CACNA1A, HTR2A, CACNA1B                                                                                                4.24*E* − 18   4.77*E* − 15
                                                                                                                                                                                                                                                                                                                     
  hsa04726   Serotonergic synapse                      10      HTR1A, PTGS2, HTR7, SLC6A4, PTGS1, MAOB, HTR2C, CACNA1A, HTR2A, CACNA1B                                                                                                                                                                1.91*E* − 08   2.14*E* − 05
                                                                                                                                                                                                                                                                                                                     
  hsa04024   cAMP signaling pathway                    11      DRD1, ADRB2, HTR1A, ADRB1, GRIN2B, ADORA2A, DRD2, CHRM2, DRD5, CHRM1, ADORA1                                                                                                                                                           2.61*E* − 07   2.93*E* − 04
                                                                                                                                                                                                                                                                                                                     
  hsa04022   cGMP-PKG signaling pathway                10      ADRB2, ADRB1, ADRA2A, ADRA1B, ADRA1A, ADRA2C, ADRA2B, ADORA1, ADRA1D, OPRD1                                                                                                                                                            4.09*E* − 07   4.60*E* − 04
                                                                                                                                                                                                                                                                                                                     
  hsa04728   Dopaminergic synapse                      9       DRD1, SCN1A, GRIN2B, DRD2, SLC6A3, DRD5, MAOB, CACNA1A, CACNA1B                                                                                                                                                                        9.69*E* − 07   0.001089
                                                                                                                                                                                                                                                                                                                     
  hsa05032   Morphine addiction                        8       OPRM1, GABRD, DRD1, GABRA2, GABRG3, ADORA1, CACNA1A, CACNA1B                                                                                                                                                                           1.23*E* − 06   0.001381
                                                                                                                                                                                                                                                                                                                     
  hsa05033   Nicotine addiction                        6       GABRD, GABRA2, GABRG3, GRIN2B, CACNA1A, CACNA1B                                                                                                                                                                                        4.20*E* − 06   0.004726
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